Fully-Human Anti-CD19 Chimeric Antigen Receptor is under clinical development by Gilead Sciences and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for B-Cell Non-Hodgkin Lymphoma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Fully-Human Anti-CD19 Chimeric Antigen Receptor’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Fully-Human Anti-CD19 Chimeric Antigen Receptor overview

Gene therapy is under development for the treatment of B-cell lymphomas such as relapsed and refractory non-Hodgkin Lymphoma including diffuse large B cell lymphoma, primary mediastinal B-cell lymphoma and transformed follicular lymphoma, B-cell lymphoma and chronic lymphocytic leukemia (CLL). The drug candidate is administered intravenously. The therapy comprises of T cells genetically modified by retroviral transduction to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19 and developed based on engineered autologous cell therapy (eACT) technology. It was also under development for B-cell leukemia, acute lymphocytic leukemia (ALL).

Gilead Sciences overview

Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. It has manufacturing facilities in Edmonton, Alberta, Canada; Foster City, San Dimas, Oceanside, California; and Cork, Ireland among others. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.

For a complete picture of Fully-Human Anti-CD19 Chimeric Antigen Receptor’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.